- Home
- VOXR vs ELDN Comparison
VOXR vs ELDN Comparison
Compare VOXR & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- ELDN
- Stock Information
- Founded
- VOXR 2014
- ELDN 2004
- Country
- VOXR United States
- ELDN United States
- Employees
- VOXR N/A
- ELDN N/A
- Industry
- VOXR Precious Metals
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- VOXR Basic Materials
- ELDN Health Care
- Exchange
- VOXR Nasdaq
- ELDN Nasdaq
- Market Cap
- VOXR 168.0M
- ELDN 178.4M
- IPO Year
- VOXR N/A
- ELDN N/A
- Fundamental
- Price
- VOXR $3.23
- ELDN $3.69
- Analyst Decision
- VOXR
- ELDN Strong Buy
- Analyst Count
- VOXR 0
- ELDN 2
- Target Price
- VOXR N/A
- ELDN $12.50
- AVG Volume (30 Days)
- VOXR 860.4K
- ELDN 837.3K
- Earning Date
- VOXR 08-06-2025
- ELDN 08-18-2025
- Dividend Yield
- VOXR 1.53%
- ELDN N/A
- EPS Growth
- VOXR N/A
- ELDN N/A
- EPS
- VOXR N/A
- ELDN N/A
- Revenue
- VOXR $10,845,445.00
- ELDN N/A
- Revenue This Year
- VOXR $16.51
- ELDN N/A
- Revenue Next Year
- VOXR $4.60
- ELDN N/A
- P/E Ratio
- VOXR N/A
- ELDN N/A
- Revenue Growth
- VOXR N/A
- ELDN N/A
- 52 Week Low
- VOXR $2.21
- ELDN $2.38
- 52 Week High
- VOXR $3.79
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- VOXR 46.91
- ELDN 70.24
- Support Level
- VOXR $3.13
- ELDN $3.67
- Resistance Level
- VOXR $3.39
- ELDN $4.09
- Average True Range (ATR)
- VOXR 0.14
- ELDN 0.22
- MACD
- VOXR 0.00
- ELDN 0.08
- Stochastic Oscillator
- VOXR 48.72
- ELDN 77.44
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.